Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at epalmer@fiercemarkets.com.

Articles by Eric Palmer

Boehringer Ingelheim still being dogged by Ben Venue plant

Boehringer Ingelheim is finding it difficult to get the stink of the troubled Ben Venue Bedford, OH, operations off its shoes. It closed the site last year and sold it last month but is still having to recall products produced there that might be contaminated.

Takeda and Lilly remain on the hook for $9B Actos award

Legal experts have insisted there is no way that a $9 billion punitive damage award against Takeda Pharmaceutical and Eli Lilly for hiding Actos risks can stand. But the two companies are still sweating that one out after a federal judge refused to throw out the verdict and its mammoth award on Thursday.

FDA says Aegerion has satisfied its demands over chatty CEO

Comments by Marc Beer, CEO of Aegerion Pharmaceuticals, got the company slapped with an FDA warning letter for exaggerating the benefits of its cholesterol-lowering drug Juxtapid during a television appearance on CNBC's "Fast Money" program. Beer had nothing to say Wednesday when the company announced the FDA had closed the matter out, satisfied with the "corrective actions" the company had taken.

Black box warning for antidepressants spelled the death of litigation

There used to be a legal specialty built by plaintiff attorneys around filing lawsuits against antidepressant makers and then settling them. But the black box warning put on antidepressants in 2004 has turned out to be a shroud for the once lucrative legal business.

Novartis CEO Jimenez shrugs off biosimilars in the short term

Swiss drugmaker Novartis last month became the first drugmaker to present the FDA with an application for a biosimilar, kicking off a new era in the U.S. that many believe will be a game changer for the industry. But from where CEO Joe Jimenez sits, it looks like no big deal for now.

Jumping into global M&A mix key to India growing its pharma industry

India's drug business has taken a big financial hit in the last years as the FDA has stopped some of its top players from shipping drugs to the U.S. But experts still see big potential in the industry, saying it will grow faster than other Indian industries, particularly if players shed their conservative approach and get involved in the global M&A mix that their larger competitors are benefiting from.

Talk gets fevered over whether Pfizer, J&J or Lilly might make a run at Cubist

The announcement that the FDA will review a second drug candidate from antibiotic specialist Cubist Pharmaceuticals, speculation is ramping up that it is ripe for a takeover.

Answer to mystery of Ranbaxy 'settlement discussions' may be found in Texas

Beleaguered Indian drugmaker Ranbaxy Laboratories set aside about $40 million in its last quarter for "ongoing settlement discussions." Now sources are suggesting the drugmaker's need for the funds: a settlement with the state of Texas.

2014 has potential to exceed milestone year of 2009 for M&A action

Pharma M&A action so far this year has been intense--so intense that if it keeps up the pace it could match the uber years of 2008 and 2010, maybe even the record year of 2009.

Lilly's strong results for psoriasis drug come on heels of data from Novartis

Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.